Log in with Facebook 
The search for an effective Covid-19 vaccine has seen some remarkable changes, with the announcement of vaccines like Pfizer and BioNTech.
The search for an effective Covid-19 vaccine has seen some remarkable changes, with the announcement of vaccines like Pfizer and BioNTech.
The global vaccine adjuvants market consists of human and veterinary adjuvants that are used to improve the efficacy of vaccines. This market is driven by several factors such as increasing government funding for research, high prevalence of diseases, expanding biotechnology and biopharmaceutical industries, and growing focus on prevention of diseases.
Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category – Forecasts to 2021
Browse 90 market data tables with 42 figures spread through 156 pages
Download PDF Brochure Now: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894
Vaccine Adjuvants market is segmented based on product type, route of administration, disease type, applications, and application category.
On the basis of product type, the market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and other adjuvants. The particulate adjuvants segment is expected to account for the largest share of the global vaccine adjuvants market in 2016.
High prevalence of infectious diseases and increasing funding for adjuvant research will drive the growth of this market segment.
Based on route of administration, the vaccine adjuvants market includes oral route, subcutaneous route, intranasal route, intramuscular route, intradermal route, and other routes. The intramuscular segment is expected to account for the largest share of the global market in 2016. Rising geriatric population and vaccines for improved immunization are the key factors propelling the growth of this market.
Request Sample Report of vaccine adjuvants market : https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894
Regional Growth, Development and Demand Analysis:
The global vaccine adjuvants market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is expected to witness the highest CAGR, with the growth in this market centered at China and India. Rising prevalence of infectious diseases, increasing government investments for vaccine research and development, rising number of conferences and symposiums, and high growth in the Indian biotechnology sector are the major factors driving the market in the Asian region.
Key Players:
Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).
Customization Options:
1. Company Information: Detailed company profiles of five or more market players
2. Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market
The global vaccine adjuvants market consists of human and veterinary adjuvants that are used to improve the efficacy of vaccines. This market is driven by several factors such as increasing government funding for research, high prevalence of diseases, expanding biotechnology and biopharmaceutical industries, and growing focus on prevention of diseases.
What Drives the Market?
1. Increasing Use of Adjuvants in Vaccine
2. High Prevalence of Infectious and Zoonotic Diseases
3. Increase in Livestock and Instances of Diseases
4. Increasing Focus on Immunization Programs From Various Government Bodies
5. Technological Advancements in Aluminum Hydroxide-Based Adjuvants
The research applications segment is expected to account for the largest share of the market during the forecast period. The human vaccine adjuvants segment is expected to account for the largest share of the global market in 2016 and is expected to have a higher growth rate in the application category segment.
Get a sample PDF copy of the Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894
The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.
On the basis of product type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment is expected to account for the largest share of the global market in 2016.
On the basis of disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and others. The infectious diseases segment is expected to account for the largest share of the global market in 2016. Factors such as high prevalence of infectious diseases, government & company initiatives, and high prevalence of cancer cases are expected to drive market growth in the coming years.
The geographical regions mapped in the report are:
1. North America
2. Europe
3. Asia-Pacific
4. Rest of the World (RoW)
The vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries
Some key players mentioned in the research report are:
Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).
Get Sample Report @https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894
